The Lancet Archives

Presented at ASCO GU 2025, results of the phase 3 TALAPRO-2 trial support a new standard-of-care for metastatic castration-resistant prostate cancer

Results of the multi-center, international phase 3 TALAPRO-2 trial show that the combination of PARP inhibitor talazoparib plus anti-androgen enzalutamide…

Copia de Copia de Copia de Banner web VHIO (8)

First targeted radioligand therapy to demonstrate significant and clinically meaningful impact in first-line advanced gastroeneropancreatic neuroendocrine tumors

Co-authored by Jaume Capdevila, Medical Oncologist at the Vall d’Hebron University Hospital (HUVH) and Senior Investigator of the Vall d’Hebron…

Changing the therapeutic landscape for patients with refractory metastatic colorectal cancer: FRESCO-2

Results of the study FRESCO-2 show a statistically and clinically meaningful benefit with a favorable safety profile in patients with…

CONTACT-03: underscoring the need to identify new treatment strategies in metastatic renal cancer after disease progression with prior immunotherapy

Led by Toni K. Choueiri at the Dana Farber Cancer Institute, Harvard Medical School in Boston (USA), the CONTACT-03 study…